Summaries of health policy coverage from major news organizations
GSK To Reduce Price of Some Antiretrovirals Sold in Developing Nations
GlaxoSmithKline on Tuesday announced that it is reducing by about 30% the cost of some of its antiretroviral drugs currently sold at not-for-profit prices in developing countries, Reuters reports. Under the cost reductions, which will take effect on July 1, 60-tablet packs of Trizivir and Ziagen will cost about $70.00 and $52.29, respectively (Reuters, 5/30). The drug company also announced that it will make Kivexa and Telzir available at not-for-profit prices once they have been approved by drug regulatory bodies in developing nations (GSK release, 5/30). GSK plans to differentiate drug shipments intended for not-for-profit markets to ensure they are not diverted back to for profit markets. In addition, the company has signed its eighth voluntary licensing agreement with South Africa-based Sonke Pharmaceuticals, which will allow Sonke to make generic versions of some of its drugs (Reuters, 5/30). In 2003, GSK announced that it was reducing the price of its AIDS drugs by as much as 47% for 63 nations, including all of sub-Saharan Africa. The reduced pricing scheme is available to not-for-profit groups, governments, aid agencies and companies that provide the drugs to their employees (Kaiser Daily HIV/AIDS Report, 4/28/03).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.